Qnovia, Inc., a clinical-stage pharmaceutical company, today announced it has secured a worldwide exclusive license to an innovative antimicrobial peptide from the University of Virginia Licensing & Ventures Group. The license marks Qnovia’s expansion into a second major therapeutic area, complementing its lead smoking cessation program as the company pursues breakthrough solutions to population-scale health challenges.
UVA Health researchers have found that gliomas, the most common primary brain tumors in adults, may be more receptive to focused ultrasound drug delivery than normal brain tissue.
A UVA neurologist explains what global transient amnesia is, and what remains a mystery.
Deloitte-funded research opportunities are giving UVA BSDS students experience tackling real problems, from healthcare to street safety to 3D generative models.
But the count will still hit 370 million by 2050, says the Weldon Cooper Center for Public Service.
These Hoos are spending their summer at the 712-acre research facility, tackling real-world research.
GET THE STORIES BEHIND THE RESEARCH
Receive updates about the discoveries, researchers, and ideas shaping our world — straight from UVA.
A University of Virginia School of Medicine scientist has received a $6.5 million grant to develop the “lymphatic medicine exam of the future” to improve care for chronic swelling, known as lymphedema, and other lymphatic diseases.
Research scientist Danielle Waterfield believes AI, when used appropriately, might help lighten the often-overwhelming workload of special education teachers.
Outbreaks, misinformation, and what network science says we should do to stop the next pandemic: A Q&A with UVA Data Science Professor YY Ahn.
MBA students are increasingly looking beyond tech startups to acquire “boring” blue-collar businesses like HVAC, plumbing, and landscaping firms. Darden professor Les Alexander explains why these businesses offer compelling fundamentals, AI disruption resistance, and strong growth potential — and how an unprecedented wave of Baby Boomer retirements is creating a rare window of opportunity for aspiring entrepreneurs through acquisition.
UVA’s Center for Systems Analysis of Stress-adapted Cancer Organelles (SASCO) recently held its annual symposium, hosting a pair of leading figures in breast cancer research and sharing findings including identification […]
UVA scientists have developed a promising new approach to targeting glioblastoma, the most common and deadliest brain cancer, that could overcome limitations of existing drugs.